Back

An angiopoietin-2 vaccine improves arteriovenous malformation pathology in hereditary hemorrhagic telangiectasia mice

Qutaina, S.; Zhao, H.; Wang, Z.; Ivaldo, C.; Ruiz, S.; Marambaud, P.

2025-10-15 cell biology
10.1101/2025.10.13.682178 bioRxiv
Show abstract

Hereditary hemorrhagic telangiectasia (HHT) is a genetic vascular disorder that causes systemic arteriovenous malformations (AVMs) associated with severe complications. Angiopoietin (ANG)-2 has been identified as a consistently upregulated secreted protein across various HHT models, and neutralizing ANG2 reduces AVMs in mice. ANG2 has thus emerged as a potential target for HHT treatment. Here, we report the development of a peptide vaccine (ANG2-P3:CRM197) that selectively targets ANG2 over ANG1 and tested its effectiveness in decreasing retinal AVMs in neonatal mice injected with BMP9/10 blocking antibodies, a model of HHT. Litter groups from female C57BL/6 mice immunized with ANG2-P3:CRM197 received injections of anti-BMP9/10 antibodies, and their retinas were examined for vascular pathology. The potential toxicity of the vaccine was evaluated in females 12 months post-immunization through echocardiography, basic metabolic panels, and lipid profiles. Circulating anti-ANG2 antibodies were detected in nursing neonates of vaccinated females, with antibody levels comparable between litters and their dams, indicating effective antibody transfer from the dams. A significant decrease in AVM number and size was observed in the retinas of pups exposed to ANG2-P3:CRM197 antibodies compared to unexposed pups. Arterial and venous diameters were normalized in the vaccinated pups retinas. The vaccinated females showed no abnormalities in cardiac, liver, or kidney functions. A vaccine strategy targeting ANG2 appears safe and improves AVM pathology in HHT mice. These findings further support the potential of inhibiting ANG2 as a viable approach for treating AVMs in HHT. KEY POINTSO_LIA peptide vaccine that targets ANG2 reduced AVM number and size, and normalized arterial and venous diameters in a mouse model of HHT. C_LIO_LIThe vaccine did not cause any abnormalities in cardiac, liver, or kidney functions, and thus appeared safe. C_LI

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Angiogenesis
15 papers in training set
Top 0.1%
13.1%
2
PLOS ONE
4510 papers in training set
Top 15%
12.7%
3
British Journal of Haematology
15 papers in training set
Top 0.1%
10.4%
4
Journal of Thrombosis and Haemostasis
28 papers in training set
Top 0.1%
6.6%
5
Arteriosclerosis, Thrombosis, and Vascular Biology
65 papers in training set
Top 0.5%
5.0%
6
Scientific Reports
3102 papers in training set
Top 30%
4.1%
50% of probability mass above
7
Journal of the American Heart Association
119 papers in training set
Top 2%
3.2%
8
Fluids and Barriers of the CNS
21 papers in training set
Top 0.1%
2.7%
9
EMBO Molecular Medicine
85 papers in training set
Top 1%
1.9%
10
Frontiers in Cardiovascular Medicine
49 papers in training set
Top 2%
1.7%
11
JACC: Basic to Translational Science
15 papers in training set
Top 0.2%
1.7%
12
Orphanet Journal of Rare Diseases
18 papers in training set
Top 0.3%
1.5%
13
The American Journal of Pathology
31 papers in training set
Top 0.2%
1.4%
14
Frontiers in Genetics
197 papers in training set
Top 6%
1.4%
15
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 7%
1.0%
16
Frontiers in Medicine
113 papers in training set
Top 5%
1.0%
17
BMJ Open
554 papers in training set
Top 11%
0.9%
18
Vaccines
196 papers in training set
Top 2%
0.9%
19
Vaccine
189 papers in training set
Top 2%
0.9%
20
JCI Insight
241 papers in training set
Top 6%
0.9%
21
Journal of Comparative Neurology
66 papers in training set
Top 0.7%
0.8%
22
Acta Biomaterialia
85 papers in training set
Top 0.8%
0.8%
23
Experimental Neurology
57 papers in training set
Top 1%
0.8%
24
Blood
67 papers in training set
Top 1%
0.8%
25
Frontiers in Immunology
586 papers in training set
Top 8%
0.7%
26
Human Mutation
29 papers in training set
Top 0.7%
0.7%
27
Cancer Medicine
24 papers in training set
Top 2%
0.5%
28
Annals of Translational Medicine
17 papers in training set
Top 2%
0.5%
29
Blood Advances
54 papers in training set
Top 2%
0.5%
30
F1000Research
79 papers in training set
Top 6%
0.5%